group of patients with and without NPS were 5.44±2.03, 3.45±1.82; respectively (P<0.001). Pain was most frequently seen in wrist-hand (50.6%) and ankle-foot (43.4%) regions; albeit, NPS rates were highest in face (94.4%), lower leg (87.5%) and gluteal (78.6%) regions. SF 36 scores were lower in patients with NPS than the patients without NPS but the difference has not reached to a statistically significant level (P>0.05). The most associated factors with NPS were Medsger Disease Severity Score for muscle and drug consumption of the patient. Conclusions: According to our results, high frequency of NPS is seen in SSc patients, and NPS is associated with low QoL. The highest rates of NPS presence were seen in face, gluteal and lower leg regions of the body. , with a diagnosis of SSc and a history of dysphagia underwent a dynamic and morphological study of the oral, pharyngeal and esophageal phases of swallowing with videofluoroscopy. The oral and pharyngeal esophageal phases were performed in the upright position, while the esophageal phase was performed in the proneoblique position, after administration of contrast material either in bolus form or diluted. Data were analyzed by radiologist with experience in videofluoroscopy for the evaluation of 17 videofluoroscopy items, of which, 4 concerning the oral, 4 the pharyngeal and 9 the esophageal phase, respectively. Results were expressed in a binary system. Then the main relevant videofluoroscopy findings were correlated with the principal scleroderma pattern of disease: lSSc vs dSSc; disease duration (more than 2 years) and subset of autoantibodies.
Conclusions: Our study demonstrated relevant abnormalities in swallowing functions in high number of patients with SSc. Pharyngeal and esophageal phases are the most affected, also early. Swallowing disorders increase with disease progression and involve similarly the limited or the diffuse SSc. An early and detailed diagnosis, supported by a semi-quantitative analysis with the use of videofluoroscopy scores, may be useful to guide the appropriate therapeutic approach, either rehabilitative or pharmacological, and finally, to improve the patient's quality of life. Extensive studies are necessary to confirm and transfer our data into clinical practice. Background: Systemic sclerosis (SSc) is characterized by fibrosis of the skin and visceral organs, especially digestive tract, and musculoskeletal involvement, which limit mobility/self-sufficiency of patients, and can have a negative impact on body composition. Objectives: To assess body composition and physical activity of SSc patients and healthy controls (HC). Methods: 59 patients with SSc (50 females, 9 males; mean age 52.1; disease duration 6.7 years; limited cutaneous (lcSSc,36)/diffuse cutaneous (dcSSc,23)) and 36 age-/sex-matched HC (30 females, 6 males, mean age 51.4) without rheumatic/tumor diseases or manifest cardiovascular event were included. SSc patients fulfilled EULAR/ACR 2013 criteria. Anthropometric parameters and body composition were assessed (by densitometry-iDXA Lunar, and by bioelectric impedance-BIA-2000-M), and physical activity was evaluated using Human Activity Profile (HAP) questionnaire. Routine biochemistry analysis was performed after 8 hours of fasting. Disease activity was evaluated by EUSTAR SSc activity score. Background: Systemic sclerosis (SSc) is a fibrotic disease which can lead to reduced maximal mouth opening (MMO). Previous cross-sectional research showed that reduced MMO in SSc correlated with higher disease severity and lower oral quality of life. Interpretation of interventions that possibly influence MMO is difficult, as the natural history of MMO in SSc is not well described. Objectives: To evaluate in SSc 1) the course of MMO 2) disease characteristics predictive for decreasing MMO and 3) the relationship between the course of MMO and global functioning, health-related quality of life (HRQoL) Results: 382 patients were included with mean age 54±14 years, 83% female and 25% diffuse cutaneous SSc. Mean MMO during 6 years of follow-up ranged from 39.4 to 42.5 mm. The annual mean percentage of patients with microstomia was 9%, range 6 to 12% (Figure 1a) . A decrease in MMO between two consecutive annual measurements was observed in 5 to 17% of patients, mean 12% ( Figure  1b ). More extended cutaneous involvement, peripheral vasculopathy, pulmonary and gastrointestinal involvement at baseline were predictive for decreasing MMO over time (Table 1) . Baseline HAQ (β=-1.6, 95% CI=-2.7 to -0.6), SF-36 physical component (β=0.1, 95% CI=0.0 to 0.1) and MHISS (β=-0.2, 95% CI=-0.2 to -0. Mi-2, Jo-1, SRP, PL-7, PL-12, EJ, OJ) and Myositisassociated autoantibodies (MAA; Ku, PM-Scl) at the same time, which is used commercially in Western countries. However, the difference between utility of MESA and that of EURO haven't be disclosed. Objectives: To clarify difference between utility of EURO and MESA, and extract the problem of respective examination. Methods: We enrolled 58 patients diagnosed DM/PM in our facility. Polymyositis (PM) and dermatomyositis (DM) were diagnosed according to Bohan and Peter's criteria.
1) The MAA and MSA were analyzed using MESA and EURO. In case of MESA (+), MSA (anti-Jo1, anti-PL7, anti-PL12, anti-KS) were identified by specific ELISA. When those results were different, we analyzed by immunoprecipitation. And we analyzed the association between each autoantibody and clinical features. Results: MSA and MAA were detected in 43/58 (74%) (anti-PL7: 12, anti-Jo1: 7, anti-EJ: 3, anti-PL12: 1, anti-OJ: 0, anti-Ro52: 27, anti-PM-Scl75: 7, anti-Ku: 6, anti-PM-Scl100: 1) by EURO. On the other hand, MSA and MAA were detected in 30/58 (52%) (anti-PL7: 9, anti-Jo1: 7, anti-EJ: 4, TIF1γ: 4, MDA5: 3, U1RNP: 3) by MESA. Five patients were MESA (-) and EURO (-). In the case of ARS positive patient, Two of EURO (-) patients was positive in MESA, respectively Jo1 and EJ. Three of MESA (-) patients was positive in EURO. Although MESA(-) and EURO(+) patients had plural MSA and MAA (PL7+Jo1, PL7+PL12, PL7+Ku), MSA and MAA weren't detected by immunoprecipitation in MESA(-) and EURO(+) patients. Two of patients that detected plural MSA or MAA had rapid progressive ILD.
(Association between clinical manifestations and MSA, MAA) All patients with anti-ARS (anti-Jo-1, anti-PL-7, anti-PL-12 and anti-EJ) had ILD. In addition, anti-ARS were associated with arthritis and mechanic's hands. Anti-Mi-2 positive patients didn't have ILD. Patients detected anti-PM-Scl75, anti-PM-Scl100, anti-Ku were almost overlap syndrome. All of Anti-SRP positive patients was PM. Conclusions: EURO is a convenient and reliable method useful for detection of MSA and MAA. It was suggested the patients whom plural antibodies were detected by EURO have unique clinical course in others. 
